Literature DB >> 4356685

Circulating interferon in rabbits after administration of human interferon by different routes.

K Cantell, L Pyhälä.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4356685     DOI: 10.1099/0022-1317-20-1-97

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


× No keyword cloud information.
  13 in total

1.  Production of human lymphoblastoid interferon.

Authors:  H Strander; K E Mogensen; K Cantell
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

Review 2.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

3.  RNase activity in human interferon preparations.

Authors:  R A Winchurch; T P Karpetsky; C C Levy; K Cantell
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

4.  Antiviral effects of interferon on a somatic cell hybrid between two Burkitt's lymphoma cell lines of different interferon sensitivities.

Authors:  B Lidin; E W Lamon
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

5.  Human leukocyte interferon: separation of biologically different species by modification of carbohydrate moieties.

Authors:  M G Salit; C A Ogburn
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  Multiple active sites on human interferons.

Authors:  K Paucker; B J Dalton; C A Ogburn; E Törmä
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

7.  The role of sialic acid in determining the survival of circulating interferon.

Authors:  V Bocci; A Pacini; G P Pessina; V Bargigli; M Russi
Journal:  Experientia       Date:  1977-02-15

8.  Potentiation of enteral absorption of human interferon alpha and selective transfer into lymphatics in rats.

Authors:  H Yoshikawa; K Takada; Y Satoh; N Naruse; S Muranishi
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

9.  Development of Interferon Suppositories. I. Enhanced Rectal Absorption of Human Fibroblast Interferon by Fusogenic Lipid via Lymphotropic Delivery in Rats.

Authors:  H Yoshikawa; K Takada; Y Satoh; N Naruse; S Muranishi
Journal:  Pharm Res       Date:  1986-04       Impact factor: 4.200

Review 10.  Oromucosal Administration of Interferon to Humans.

Authors:  Manfred W Beilharz; Martin J Cummins; Alayne L Bennett; Joseph M Cummins
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.